Cohen C, Berson S D, Shulman G, Budgeon L R
Cancer. 1984 May 1;53(9):1931-5. doi: 10.1002/1097-0142(19840501)53:9<1931::aid-cncr2820530921>3.0.co;2-d.
Serum ferritin concentrations are elevated in 35% to 100% of patients with hepatocellular carcinoma (HCC). With an immunoperoxidase technique, ferritin was demonstrated in tumor tissue from 32 of 74 (43%) black southern African patients, and from 12 of 19 (63%) American patients with HCC (P greater than 0.1). Ferritin was present in nonneoplastic liver in 82% of African and 100% of American patients (P greater than 0.1). Moderate to large amounts of stainable hepatic storage iron (hemosiderin) were present in 76% of African and 67% of American patients (P greater than 0.1). Fifty-two (70%) African patients had macronodular cirrhosis. In the literature, 80% to 90% of American patients with HCC have cirrhosis. High serum ferritin levels in patients with HCC may be due to ferritin production by the tumor, or related to the associated iron overload and/or cirrhosis.
在35%至100%的肝细胞癌(HCC)患者中,血清铁蛋白浓度会升高。采用免疫过氧化物酶技术,在74名南非黑人患者中的32名(43%)以及19名美国HCC患者中的12名(63%)的肿瘤组织中检测到了铁蛋白(P大于0.1)。在82%的非洲患者和100%的美国患者的非肿瘤性肝脏中存在铁蛋白(P大于0.1)。76%的非洲患者和67%的美国患者存在中度至大量可染色的肝脏储存铁(含铁血黄素)(P大于0.1)。52名(70%)非洲患者患有大结节性肝硬化。在文献中,80%至90%的美国HCC患者患有肝硬化。HCC患者血清铁蛋白水平升高可能是由于肿瘤产生铁蛋白,或者与相关的铁过载和/或肝硬化有关。